In models of cerebral ischemia and spinal cord injury, glibenclamide inhibition of Sur1 is associated with enhanced microglial phagocytosis and improved neurological function, with these effects attributed to inhibition of microglial Sur1-Kir6.2 (KATP) channels [32–35]. The gene discussed is ABCC8; the disease is brain ischemia.